A new review of studies underpinning the FDA’s limit on the allowable level of aluminum adjuvant per vaccine dose reveals the level, set decades ago, was determined on the basis of how well the adjuvant generated an immune response — not on whether the aluminum posed a health risk.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed